Assessment of visual outcomes in patients with endophthalmitis after OZURDEX injection
Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
This study is testing how well vision and eye pressure improve in patients who develop endophthalmitis after receiving an OZURDEX injection over the course of a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 8 (estimated) |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 1 site (Saint-Étienne) |
| Trial ID | NCT06268561 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients who develop endophthalmitis following an OZURDEX implant injection. It aims to assess the prognosis of visual acuity and intraocular pressure over a 12-month period. The methodology includes detailed analyses of optical coherence tomography (OCT) images and retinograms to evaluate the condition's impact on vision. By monitoring these parameters, the study seeks to provide insights into the functional prognosis for affected patients.
Who should consider this trial
Good fit: Ideal candidates are patients who have experienced endophthalmitis within two months following an OZURDEX injection.
Not a fit: Patients who have undergone any intraocular procedures between the OZURDEX injection and the onset of endophthalmitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of visual outcomes in patients with endophthalmitis, leading to better management strategies.
How similar studies have performed: While there may be limited studies specifically on OZURDEX-related endophthalmitis, similar observational studies have shown promise in understanding treatment outcomes for ocular conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient who had endophtalmitis following an OZURDEX implant injection within 2 months Exclusion Criteria: * Intra oculaire procedure in the interval between the injection of OZURDEX and endophtalmitis
Where this trial is running
Saint-Étienne
- CHU Saint Etienne — Saint-Étienne, France (Recruiting)
Study contacts
- Principal investigator: Thibaud GARCIN, MD PhD — Chu Saint-Etienne
- Study coordinator: Thibaud GARCIN, MD PhD
- Email: thibaud.garcin@chu-st-etienne.fr
- Phone: (0)477829662
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.